{
    "links": "https://www.ycombinator.com/companies/valink-therapeutics",
    "name": "Valink Therapeutics",
    "headline": "Discovering bispecific antibody drug-conjugates (BsADC) against cancer",
    "batch": "W21",
    "description": "Valink Therapeutics develops next generation antibody-based therapeutics. We identify novel mechanism of action from known targets by incorporating multiple antibody modifications at once, rapidly and scalable generating complex drug candidates (bi-/multispecificity, multivalency and drug-conjugation in a single discovery process). Our research focus is on solid tumours poorly addressed by immunotherapy.",
    "activity_status": "Active",
    "website": "https://www.valinktx.com/",
    "founded_date": 2021.0,
    "team_size": 14.0,
    "location": "Boston",
    "group_partner": null,
    "group_partner_yc": null,
    "company_linkedin": null,
    "company_twitter": null,
    "tags": "industry:biotech; industry:therapeutics; industry:drug-discovery; location:boston",
    "founders": [
        {
            "name": "Arne Scheu, Founder",
            "description": "Rhodes Scholar & DPhil Biochemistry from the University of Oxford",
            "linkedin": "https://www.linkedin.com/in/arne-scheu-aa22b812b/"
        },
        {
            "name": "Irsyad Khairil, Founder",
            "description": "Pharma analyst with a background in protein engineering\nDPhil in Biochemistry from the University of Oxford",
            "linkedin": "https://www.linkedin.com/in/irsyad-khairil-bb216b9b/"
        }
    ],
    "status": true,
    "generated_description": "**Valink Therapeutics: Innovating Cancer Treatment with Bispecific Antibody Drug Conjugates**\n\nFounded in 2021 as part of Y Combinator's Batch W21, Valink Therapeutics is a Boston-based biotech company focused on transforming cancer treatment through the development of bispecific antibody drug conjugates (bsADCs). Their mission is to discover more effective drugs targeted at solid tumors, areas of cancer biology that have been poorly addressed by existing immunotherapies.\n\n### What's Special About Valink?\n\nValink operates on a cutting-edge technology platform, LiliumX\u2122, which allows for rapid design and testing of novel drug candidates. Unlike traditional methods that can take months to generate potential treatments, Valink's approach can produce thousands of drug candidates within days by incorporating multiple modifications to antibodies at once. This multitasking capability enhances their ability to create complex drug candidates that feature bi- and multispecificity, multivalency, and drug-conjugation\u2014all in one streamlined process.\n\n### The Science Behind the Solutions\n\nThe bsADCs developed by Valink use a dual-targeting mechanism, enabling improved efficacy by more precisely delivering therapeutic payloads to malignant tissues while sparing healthy cells. This is particularly important in treating solid tumors where distinguishing between cancerous and healthy cells can be a significant challenge. By targeting two markers simultaneously, Valink's drugs hold the promise of being not just more effective but also safer.\n\n### The Team and Investors\n\nWith a compact team of 14 employees, Valink leverages the expertise and resources from prestigious backers, including RV Invest, Hoxton Ventures, and others, underscoring confidence in their innovative approach to drug discovery.\n\n### The Road Ahead\n\nValink Therapeutics is on a mission to unlock unprecedented therapies that will change the game in oncology. As they continue their work, we can look forward to new developments that could significantly improve outcomes for patients battling cancer.\n\nFor more details, visit their [website](https://www.valinktx.com/).",
    "logo": "https://bookface-images.s3.us-west-2.amazonaws.com/logos/c8725d7a993ab662666861afa9b3a27f0d00f762.png?X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Credential=ASIAQC4NIECANZTIEPER%2F20250221%2Fus-west-2%2Fs3%2Faws4_request&X-Amz-Date=20250221T192040Z&X-Amz-Expires=3600&X-Amz-Security-Token=IQoJb3JpZ2luX2VjELP%2F%2F%2F%2F%2F%2F%2F%2F%2F%2FwEaCXVzLXdlc3QtMiJGMEQCIFK7AaY6pLW7VXlabKqUnsti6Yla%2FSCoewpy2UpIVCaCAiA8ht7ARDxEtPYflXgJ6GN5bEZeebWfnDTKyeidmcTC1CruAwjc%2F%2F%2F%2F%2F%2F%2F%2F%2F%2F8BEAAaDDAwNjIwMTgxMTA3MiIMCT%2BNNvy1oYZVQ2WfKsIDC8tFQP9udIDUz7fPe0Dzhi3kRbDHT6z1su5L4S2TNId9sdGLXlMH5QJEjIRQ0rRGFxtFwHq3Ei%2FFUMz8Ks%2BREJfMgSTVpukyJgwEShybEje0ZmE8QmQZfZHBoB3xkrE%2BBayG5FX4vDwLgpeUOm2x0Sme6SqEGp0U2HdP5J9we04xpSN6O3pOAmTuuCsb%2BQPYCH1mXWSVmvNh2pUbfVpEuA1sb0Wiptbpfnhy4N1sMbsvgcVHnJWsfFM7KpvOlLi74Nr4Vc0xdBaCVKFI%2F41dQ8B4Kzz9dYpoaJusn%2BzTCogghYP7kOh6JJVWY35TuATGcnfRj43am6HEi642klk52iMuE3ArHBew3k4kXFjbnK43UVyRzTS05n6rrFGghTnrTREChlc9QCNp9k3yv2JDnt3mmhgvF7SgDPlQjN30occWCFX7TKX0SeOYyEtGYGTfIgd7vhxYn9lJ4oKAdWFyyag09TH2uQboF8DUZi4%2Fg8KcUmexxB%2F6WrTdTaOmKfNgD1HgHc3rUIip1aKJOxhl%2FK2vVvuv24UBvRE8k9cA9IRmUWpABHCRsWHi18byrwhB8loeVL%2B%2FJ0OsbjBfCFm%2Bw6q1MLKL470GOqYBVYJ7J0xnXg6%2FzqB9gfoZM97xPrmQD13S%2F2Fk8gtkTcxCMI3BWSeNqsOoiP1%2Fd0GbOsuEccJaBnW%2B4rCnpLm49esEX6GFb5TSj2RJpw0MiIDCBDehJEL0xBmL41NHVEKuK%2Fj6JCSGHAzPKoaj%2FQs%2BQ0%2BmDRURurQUk6EIMYr867Y%2BX2Rq%2FtjXqF5VR7HKdT0IVHTM96uCnswQE%2FjhiCPclPGbctMWJQ%3D%3D&X-Amz-SignedHeaders=host&X-Amz-Signature=aef6c9f65c460aa738a3cd98b2008c0a4ecb348d07f5ae5cd1519800276d96dd",
    "social_links": [
        "https://www.linkedin.com/company/71180674/"
    ],
    "logo_path": "data/logos\\Valink_Therapeutics_logo.png"
}